Zheng Quan Zhi Xing·2025-06-12 14:09Core Viewpoint - The report outlines the verification opinions regarding the listing and circulation of strategic placement restricted shares of Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. following its initial public offering on the Sci-Tech Innovation Board [1][5]. Summary by Sections 1. Type of Restricted Shares - The company issued 91,680,000 shares during its IPO, with a total share capital of 366,680,000 shares post-IPO. The restricted shares amount to 2,639,915 shares, representing 0.7200% of the total share capital, with a lock-up period of 24 months starting from June 20, 2023 [1][2]. 2. Changes in Share Capital - Since the formation of the restricted shares, there have been no changes in the company's share capital due to profit distribution or capital reserve transfers [2]. 3. Commitments Related to Restricted Shares - The shareholder, Haitong Innovation Securities Investment Co., Ltd., has committed to a lock-up period of 24 months from the IPO date. After the lock-up period, any reduction in shareholding will comply with the relevant regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange [2][3]. 4. Listing and Circulation of Restricted Shares - The restricted shares will be listed and available for circulation on June 20, 2025. The total number of shares for circulation is 2,639,915, which is the entire amount of strategic placement shares [3][4]. 5. Verification Opinions from the Sponsor - The sponsor, Guotai Junan Securities Co., Ltd., confirms that all commitments made by the restricted share shareholders have been strictly adhered to, and the listing and circulation of the restricted shares comply with relevant regulations [4][5].